DocStoX is a free AI-powered research platform for Indian equity markets, covering 5,700+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (5,700+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 93 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Neutral impactCompany

Awfis Space Solutions Limited — Certificate under SEBI (Depositories and Participants) Regulations, 2018

NSE 2 hrs ago·12 Oct 2026, 12:34 pm

Awfis Space Solutions

Awfis Space Solutions Limited has informed stock exchanges that it has obtained a certificate under SEBI’s Depositories and Participants Regulations, 2018. This document confirms that the company is in compliance with the regulatory framework governing its shareholding patterns and depository operations.

For investors, this development is largely procedural and signals that Awfis is maintaining adherence to the rules set by the market regulator. It does not indicate any financial distress or operational halt. Such filings are routine for companies with listed securities to ensure transparency and regulatory compliance.

Investors should monitor the company’s quarterly results and occupancy levels in its co-working spaces to gauge its actual business performance, rather than focusing on this regulatory filing.